Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston and Thoratec hold their ground despite troubles while Zimmer exceeds expectations

This article was originally published in Clinica

Executive Summary

American Medical Systems (AMS) saw its second quarter and half year profits boosted by 33% and 40%, respectively. The Minneapolis company attributed revenue growth to strong sales of its women continence products, which increased 52% compared with the same period last year, as well as male continence products, which showed a healthy growth of 17%. Erectile restoration, which accounts for the largest segment of AMS' men's health product line, was flat compared to last year's second quarter, but the company is expecting it to gather momentum, following the recent FDA clearance of the AMS 700 tactile pump. In addition, Minneapolis-based AMS is hoping the acquisition of TherMatrx (see Clinica No 1113, p 13) will provide another growth engine and the means to expand into the high-growth, in-office benign prostatic hyperplasia market.

You may also be interested in...

HHS Policy Move Means FDA Must Publish More Documentation To Support Rulemaking Decisions

To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts